nintedanib IPF
Selected indexed studies
- Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis. (BMC Pulm Med, 2021) [PMID:34895203]
- Interstitial Lung Disease: A Review. (JAMA, 2024) [PMID:38648021]
- Comparison of Pirfenidone and Nintedanib: Post Hoc Analysis of the CleanUP-IPF Study. (Chest, 2024) [PMID:38030064]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis. (2021) pubmed
- Interstitial Lung Disease: A Review. (2024) pubmed
- Comparison of Pirfenidone and Nintedanib: Post Hoc Analysis of the CleanUP-IPF Study. (2024) pubmed
- Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. (2015) pubmed
- Nintedanib Ameliorates Bleomycin-Induced Pulmonary Fibrosis, Inflammation, Apoptosis, and Oxidative Stress by Modulating PI3K/Akt/mTOR Pathway in Mice. (2023) pubmed
- Idiopathic pulmonary fibrosis. (2023) pubmed
- Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis. (2025) pubmed
- Nintedanib: A Review in Fibrotic Interstitial Lung Diseases. (2021) pubmed
- Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. (2020) pubmed
- Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis: The INTEGRIS-IPF Clinical Trial. (2024) pubmed